DAB2 and non-small cell lung carcinoma: Ma et al. also found that lower DAB2 expression correlated with higher TNM status, more frequent metastases, and worse outcomes in non-small-cell lung cancer, and suggested that DAB2 could become a new prognostic and predictive biomarker, especially in DAB2 hypermethylated tumors [37].